To aloud OPDIVO in the UK not just Scotland sooner then a year.

Advanced Squamous NSCLC Trial
In a clinical trial of 272 patients whose advanced squamous NSCLC had spread or grown after treatment with platinum-based chemotherapy, 135 were treated with OPDIVO, 137 were treated with chemotherapy (docetaxel). OPDIVO was shown to reduce the risk of dying by 41% compared to chemotherapy (docetaxel). Half of the patients on OPDIVO were still alive at 9.2 months, compared to 6 months with chemotherapy (docetaxel). OPDIVO will not work for everyone. Individual results may vary